Novo hunts for ‘maximum potential’ from obesity drug CagriSema

Novo Nordisk’s amylin obesity drug keeps performing like Zepbound

CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on safety and efficacy, further data indicating that CagriSema may not be the standout treatment that investors had hoped for. Novo previously reported that patients on CagriSema lost 20% of their weight in a 68-week Phase 3 trial when looking at all participants, a similar level of weight loss seen in Zepbound studie…

Novo hunts for ‘maximum potential’ from obesity drug CagriSema

Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target